

PRESS RELEASE
Uppsala
September 18, 2009

Q-Med trading update for the third quarter of 2009

In order to ensure that shareholders have up to date information, Q-Med has deemed it appropriate to provide an interim trading update for the third quarter of 2009. However, it should be noted that there remains a high degree of uncertainty given the current economic environment.

Q-Med's revenues in July and August 2009 have been lower than in the same period in 2008. If revenue development continues at the same rate for the rest of the quarter, total revenues for the third quarter of 2009 will be approximately 20% lower than the same period in 2008. This has contributed to a lower overall operating profit margin for July and August compared to the same period in 2008. Assuming that the operating profit margin for July and August is maintained for the rest of the quarter, the overall operating profit for the third quarter will be approximately 40 MSEK.

Queries should be addressed to:

Alexander Kotsinas, Vice President and CFO

Tel: +46 735 00 1111

Karin Falck, Director Corporate Communications

Tel: +46 70 974 9015

Q-Med AB is a medical device company. The company develops, manufactures, markets, and sells primarily medical implants. The majority of the products are based on the company's patented technology, **NASHA™**, for the production of stabilized non-animal hyaluronic acid. The product portfolio today contains: **Restylane®** for filling lines and folds, contouring and creating volume in the face, **Macrolane™** for body contouring, **Durolane™** for the treatment of osteoarthritis of the hip and knee joints, **Deflux®** for the treatment of vesicoureteral reflux, VUR, (a malformation of the urinary bladder) in children, and **Solesta™** for the treatment of fecal incontinence. Sales are made through the company's own subsidiaries or distributors in over 70 countries. Q-Med today has about 650 coworkers, with approximately 400 at the company's head office and production facility in Uppsala, Sweden. Q-Med AB is listed in the Mid Cap segment of the NASDAQ OMX Nordic.
